For example, carotuximab (TRC105), an anti-endoglin monoclonal antibody, has shown promising activity in combination with sorafenib in a phase 1b/2 clinical trial of patients with treatment naïve hepatocellular carcinoma. Here, ENG is linked to hepatocellular carcinoma.